



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Oncology

RECEIVED 27 February 2023
ACCEPTED 27 February 2023
PUBLISHED 07 March 2023

CITATION
Frontiers Production Office (2023) Erratum:
Tumor response assessment on imaging
following immunotherapy.
Front. Oncol. 13:1175321.
doi: 10.3389/fonc.2023.1175321

COPYRIGHT
© 2023 Frontiers Production Office. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Erratum: Tumor response assessment on imaging following immunotherapy

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

tumor response, immunotherapy, immune checkpoint inhibitor, pseudoprogression, iRECIST, imRECIST, PERCMT, iPERCIST

An Erratum on

[Tumor response assessment on imaging following immunotherapy](#)

By Berz AM, Dromain C, Vietti-Violi N, Boughdad S and Duran R (2022) *Front. Oncol.* 12:982983. doi: 10.3389/fonc.2022.982983

An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Lausanne”.

The original version of this article has been updated.